By simultaneously delivering multiple small‐molecule prodrugs to the tumor site and releasing the primary drug at a defined point in time, this system not only achieves synergistic treatment and improves efficacy, but also dramatically reduces organ toxicity, showcasing enormous potential for cancer treatment.[18, 19] To surmount the respective limitations of CA‐4 and ES‐Cu in liver cancer treatment, CA‐4S2@ES‐Cu nanomedicine was designed and prepared in this study (Scheme1). This evidence concerns the gene CA4 and neoplasm.